Poster presentation, P67

Official XXIst International Pigment Cell Conference website - 21-24 Sept 2011, Bordeaux - France | updated: September 04 2011

Tacrolimus versus pimecrolimus in localised stable vitiligo

AIM: To compare efficacy and safety of 0.1% Tacrolimus ointment versus 1% Pimecrolimus cream in localised stable vitiligo. METHODOLOGY: 52 cases of localised stable vitiligo were randomly divided to receive 0.1% Tacrolimus ointment or 1% Pimecrolimus cream and followed up monthly for 6 months to assess repigmentation based on 7-point ordinal scale. Overall response was graded as- Poor (1-25%), Moderate (26-50%), Good (51-75%), Excellent (> 76%). RESULTS: Mean age of cases was 19 years, F/M ratio- 3:2. In 54% cases, vitiligo was < 6 months duration. Maximum repigmentation in Tacrolimus group was seen in age group 11-20 years (45%) while in Pimecrolimus group it was 21-30 years (22%). Repigmentation in both groups was more in males (50% and 27%) than females (26% and 12%). Vitiligo of duration < 1 year responded maximally (50% in Tacrolimus and 21% in Pimecrolimus group). Maximum repigmentation was seen on trunk (62%) in Tacrolimus group, while on lower extremity (33%) in Pimecrolimus group. Moderate to excellent response was seen in 39% cases in Tacrolimus against 8% in Pimecrolimus group. Burning and pruritus were present in 6% cases in both groups. CONCLUSION: Tacrolimus is more efficacious than Pimecrolimus in localised stable vitiligo when treated and monitored for 6 months.

Advertisement from our sponsor: